These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 27422203)

  • 21. TRAIL-R2 is not correlated with p53 status and is rarely mutated in non-small cell lung cancer.
    Wu WG; Soria JC; Wang L; Kemp BL; Mao L
    Anticancer Res; 2000; 20(6B):4525-9. PubMed ID: 11205299
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The race to target MET exon 14 skipping alterations in non-small cell lung cancer: The Why, the How, the Who, the Unknown, and the Inevitable.
    Reungwetwattana T; Liang Y; Zhu V; Ou SI
    Lung Cancer; 2017 Jan; 103():27-37. PubMed ID: 28024693
    [TBL] [Abstract][Full Text] [Related]  

  • 23. BRAF
    Rosell R; Karachaliou N
    Lancet Oncol; 2017 Oct; 18(10):1286-1287. PubMed ID: 28919012
    [No Abstract]   [Full Text] [Related]  

  • 24. Gene mutation analysis in non-small cell lung cancer patients using bronchoalveolar lavage fluid and tumor tissue as diagnostic markers.
    Li J; Hu YM; Wang Y; Tang XP; Shi WL; Du YJ
    Int J Biol Markers; 2014 Dec; 29(4):e328-36. PubMed ID: 24519547
    [TBL] [Abstract][Full Text] [Related]  

  • 25. BRAF mutations in sarcomatoid and large cell carcinoma of the lung-reply.
    Yvorel V; Forest F; Karpathiou G; Péoc'h M
    Hum Pathol; 2017 May; 63():220-221. PubMed ID: 27939780
    [No Abstract]   [Full Text] [Related]  

  • 26. [Mechanism of c-MET in Non-small Cell Lung Cancer and Its Treatment and Testing].
    Liang H; Wang M
    Zhongguo Fei Ai Za Zhi; 2015 Dec; 18(12):745-51. PubMed ID: 26706951
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intertumor heterogeneity of non-small-cell lung carcinomas revealed by multiplexed mutation profiling and integrative genomics.
    Tan DS; Camilleri-Broët S; Tan EH; Alifano M; Lim WT; Bobbio A; Zhang S; Ng QS; Ang MK; Iyer NG; Takano A; Lim KH; Régnard JF; Tan P; Broët P
    Int J Cancer; 2014 Sep; 135(5):1092-100. PubMed ID: 24482041
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular diagnosis of activating EGFR mutations in non-small cell lung cancer using mutation-specific antibodies for immunohistochemical analysis.
    Kawahara A; Yamamoto C; Nakashima K; Azuma K; Hattori S; Kashihara M; Aizawa H; Basaki Y; Kuwano M; Kage M; Mitsudomi T; Ono M
    Clin Cancer Res; 2010 Jun; 16(12):3163-70. PubMed ID: 20423982
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impaired c-Met Receptor Degradation Mediated by MET Exon 14 Mutations in Non-Small-Cell Lung Cancer.
    Awad MM
    J Clin Oncol; 2016 Mar; 34(8):879-81. PubMed ID: 26786927
    [No Abstract]   [Full Text] [Related]  

  • 30. Comparative analyses of individual and multiple alterations of p53, PTEN and p16 in non-small cell lung carcinoma, glioma and breast carcinoma samples.
    Stankovic T; Milinkovic V; Bankovic J; Dinic J; Tanic N; Dramicanin T; Tanic N
    Biomed Pharmacother; 2014 Jun; 68(5):521-6. PubMed ID: 24767865
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of EGFR mutation analysis in non-small cell lung cancer.
    Yamamoto H; Toyooka S; Mitsudomi T
    Lung Cancer; 2009 Mar; 63(3):315-21. PubMed ID: 18760859
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Responses to Crizotinib Can Occur in High-Level MET-Amplified Non-Small Cell Lung Cancer Independent of MET Exon 14 Alterations.
    Caparica R; Yen CT; Coudry R; Ou SI; Varella-Garcia M; Camidge DR; de Castro G
    J Thorac Oncol; 2017 Jan; 12(1):141-144. PubMed ID: 27664533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma DNA, microsatellite alterations, and p53 tumor mutations are associated with disease-free survival in radically resected non-small cell lung cancer patients: a study of the perugia multidisciplinary team for thoracic oncology.
    Ludovini V; Pistola L; Gregorc V; Floriani I; Rulli E; Piattoni S; Di Carlo L; Semeraro A; Darwish S; Tofanetti FR; Stocchi L; Mihaylova Z; Bellezza G; Del Sordo R; Daddi G; Crinò L; Tonato M
    J Thorac Oncol; 2008 Apr; 3(4):365-73. PubMed ID: 18379354
    [TBL] [Abstract][Full Text] [Related]  

  • 34. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.
    Saffroy R; Fallet V; Girard N; Mazieres J; Sibilot DM; Lantuejoul S; Rouquette I; Thivolet-Bejui F; Vieira T; Antoine M; Cadranel J; Lemoine A; Wislez M
    Oncotarget; 2017 Jun; 8(26):42428-42437. PubMed ID: 28418914
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Frequency of EGFR T790M mutation and multimutational profiles of rebiopsy samples from non-small cell lung cancer developing acquired resistance to EGFR tyrosine kinase inhibitors in Japanese patients.
    Ko R; Kenmotsu H; Serizawa M; Koh Y; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Isaka M; Endo M; Nakajima T; Ohde Y; Yamamoto N; Takahashi K; Takahashi T
    BMC Cancer; 2016 Nov; 16(1):864. PubMed ID: 27821131
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The impact of MET, IGF-1, IGF1R expression and EGFR mutations on survival of patients with non-small-cell lung cancer.
    Al-Saad S; Richardsen E; Kilvaer TK; Donnem T; Andersen S; Khanehkenari M; Bremnes RM; Busund LT
    PLoS One; 2017; 12(7):e0181527. PubMed ID: 28742836
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Unique Characteristics of MET Exon 14 Mutation in Chinese Patients with NSCLC.
    Liu SY; Gou LY; Li AN; Lou NN; Gao HF; Su J; Yang JJ; Zhang XC; Shao Y; Dong ZY; Zhou Q; Zhong WZ; Wu YL
    J Thorac Oncol; 2016 Sep; 11(9):1503-10. PubMed ID: 27257131
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The EGFR mutation status affects the relative biological effectiveness of carbon-ion beams in non-small cell lung carcinoma cells.
    Amornwichet N; Oike T; Shibata A; Nirodi CS; Ogiwara H; Makino H; Kimura Y; Hirota Y; Isono M; Yoshida Y; Ohno T; Kohno T; Nakano T
    Sci Rep; 2015 Jun; 5():11305. PubMed ID: 26065573
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reply to: Comment on 'Molecular evidence of viral DNA in non-small cell lung cancer and non-neoplastic lung'.
    Robinson LA; Jaing CJ; Campbell CP; Magliocco A; Xiong Y; Magliocco G; Thissen JB; Antonia S
    Br J Cancer; 2017 Jan; 116(3):e6. PubMed ID: 27764846
    [No Abstract]   [Full Text] [Related]  

  • 40. Detection of PIK3CA mutations, including a novel mutation of V344G in exon 4, in metastatic lung adenocarcinomas: A retrospective study of 115 FNA cases.
    Allison DB; Lilo MT; Geddes S; Pallavajjalla A; Askin F; Gabrielson E; Zheng G; Li QK
    Cancer Cytopathol; 2016 Jul; 124(7):485-92. PubMed ID: 27007084
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.